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The aim of this paper is to report the clinical characteristic of those patients reporting ‘I have 
too much saliva’ following treatment for head and neck cancer. As a new addition to the 
saliva question of the UW-QOL, another aim is to make recommendations on how this new 
option should be scored and handled.  
 
Patients treated with curative intent were recruited between April 2017 and October 2019. 
Assessment was at the first baseline clinic a median (IQR) of 194 (125-249) days after 
diagnosis and 103 (71-162) days after the end of treatment. Patients completed the modified 
UW-QOLv4, Patient Concerns Inventory (PCI), Distress thermometer, EQ-5D-5L. 
 
In 288 patients, saliva was of normal consistency for 28% (80), less than normal but enough 
for 20% (57), too little for 32% (91), too much for 16% (45), and there was no saliva at all for 
5% (15). Of patients with too much saliva, two-thirds (69%, 31/45) had tumours located in 
the oral cavity and 45% (18/40) had the highest rates of free-flap use during surgery.  
Salivation response was associated strongly with the other measures of HRQOL and the PCI. 
Of those with too much saliva their results were similar to or worse than those with too little 
saliva or with no saliva at all. 
 
In conclusion, having too much saliva is relatively less frequently reported but is an 
important HRQOL consideration. Its scoring in the UW-QOL should be at a level similar to 














There are a wide range of issues that affect head and neck cancer patients (HNC) (S N Rogers 
et al., 2016) and it is accepted that in routine practice, no one questionnaire has the ability to 
cover all aspects (Vartanian, Rogers and Kowalski, 2017). The problems patients experience 
with saliva can have profound detrimental consequences on health-related quality of life 
(HRQOL) (Høxbroe Michaelsen et al., 2017). The focus in the various patient reported 
outcome questionnaires has been reduced saliva and this has led to the development of 
xerostomia specific questionnaires.   The issue of too much saliva as an outcome has been 
relatively over looked. 
 
Too much saliva is a recognised problem for patients following for treatment for HNC 
(Bomeli et al., 2008). This can have a negative impact on the patient’s quality of life and 
often results in patients seeking treatment to resolve this issue. Treatment approaches exist, 
and therefore it is important to recognise it and offer clear management strategies. More 
frequently reported following major radical surgery and reconstruction are oral competency, 
poor lip function, poor tongue and swallowing function. This is seen with our without 
preceding RT. Even in the presence of normal saliva volume and consistency, RT can cause 
fibrosis and poor function which can lead to poor control of saliva impacting further on 
patients overall QOL. There exists only a few questionnaires that specifically ask about the 
issue of too much saliva for example Groningen radiotherapy-induced xerostomia (GRIX) 
questionnaire (Beetz et al., 2010), Drooling Severity and Frequency Scale (Li et al., 2015), 
Liverpool Oral Rehabilitation Questionnaire (LORQ)(Pace-Balzan, 2008). 
 
The three commonest questionnaires used to report HRQOL following HCN are the EORTC, 
FACT and University of Washington head and neck Cancer quality of life questionnaire 
(UW-QOL). (Kanatas and Rogers, 2008). These focus on reduced saliva. The UW-QOL was 
first published in 1993 (Hassan et al 1993) and in 2002 version 4 was published (Rogers et 
al., 2002). The UW-QOL saliva domain has four hierarchical response options ranging from 
a total lack of saliva to having saliva of normal consistency. One of the limitations when 
using the saliva domain is that some patients reported difficulty in answering it because they 
had too much saliva and this can result in slightly greater missing data rates with this domain 
compared to other domains and sometimes a free-text reference to having too much 
(Millsopp et al., 2003). 
 
The aim of this paper is to report the inclusion of ‘I have too much saliva’ into the saliva 
domain of the UW-QOL, to investigate how much of a problem having too much saliva is to 





The UW-QOLv 4 questionnaire consists of 12 single question domains, these having between 
3 and 5 response options that are scaled evenly from 0 (worst) to 100 (best) according to the 
hierarchy of response (Rogers et al., 2002). The UW-QOL V4 saliva domain has four 
possible responses scored as (100) 'My saliva is of normal consistency', (70) 'I have less 
saliva than normal, but it is enough', (30) 'I have too little saliva' and (0) ' I have no saliva. In 
regard to overall QOL, patients are asked to consider not only physical & mental health, but 
also many other factors, such as family, friends, spirituality or personal leisure activities that 
were important to their enjoyment of life. The whole questionnaire focuses on the past 7 
days, and there is also a question asking which domains (to a maximum of three) have been 
most important. Subsequent analysis has led to the development of subscale composite scores 
(Rogers et al., 2010) and domain algorithms to screen for significant problems/dysfunction 
(Rogers and Lowe, 2009). Previously, a significant problem or dysfunction with salivation 
was indicated either by someone having no saliva at all or by someone having too little saliva 
and stating that salivation had been important to them in the past week. Question domains for 
intimacy and fears of recurrence have also been developed using a similar system of possible 
hierarchical responses as the UWQOLv4 (Low et al., 2009),(Simon N. Rogers et al., 2016) 
 
The baseline data we report come from a pragmatic cluster-controlled trial, with consultants 
(clusters) randomised to ‘using’ or ‘not using’ an intervention incorporating the PCI prompt 
list at all their trial clinics. The PCI consists of 56 clinical items (Rogers and Lowe, 2009) 
which patients select from before their appointment, to help guide the outpatient consultation 
through the symptoms and problems that they may experience following their treatment for 
HNC. The methods of the PCI trial have been described previously (Rogers et al., 2018). 
Eligible patients were treated curatively for primary or secondary HNC, and all sites, stage of 
disease and treatments were included. Palliation and recurrence were exclusion criteria as 
were cognitive impairment, psychoses or dementia.   
 
Unit researchers collected baseline clinical/demographic data either via a baseline clinic 
questionnaire with demographic questions chosen as far as possible to match those included 
in the head and neck 5000 project (Ness, 2015) or by extraction from baseline clinical 
records. Baseline data included cancer site, disease severity, treatment details, gender, age 
and comorbidity.  Trial HRQOL outcome baseline data included the UW-QOLv4 (Rogers et 
al., 2002), Distress thermometer (Hegel MT, Collins ED, Kearing S, Gillock KL, Moore CP, 
2008) and the EQ-5D-5L (EuroQol 2015), and the categorisations used in this paper for these 
measures are consistent with decisions pertaining to the trial.   
 
Fishers exact test (categorical data) or the Kruskal-Wallis test (numerical data) was used to 
compare patients with different responses to the saliva domain question in regard to case-mix 
and HRQOL outcome baseline data. There was a particular focus on describing the 
characteristics and responses of those with too much saliva.  Interpretation was required to 
suggest an appropriate scoring for this option on the 0-100 saliva scale, given that patient 
saliva scores are important in the calculation of the physical function composite scale. The 
algorithm to indicate significant problems or dysfunction with salivation was also reviewed.  
 
The PCI trial has ethical approval from North West - Liverpool Central Research Ethics 
Committee REC reference: IRAS 16/NW/0465, Project ID: 189554. It also has approval 
from the Health Research Authority (HRA). The Research and Development Department at 
Aintree University Hospital NHS Trust (AUH) is coordinating the trial and AUH is the 






Trial patients with baseline data were first discussed at MDT meetings between January 2017 
and December 2018, with baseline trial clinics between April 2017 and October 2019. A total 
of 288 patients attended trial baseline clinics a median (IQR) of 194 (125-249) days after 
diagnosis and 103 (71-162) days after the end of treatment. 
Saliva was of normal consistency for 28% (80) of patients, less than normal but enough for 
20% (57), too little for 32% (91), too much for 16% (45), and there was no saliva at all for 
5% (15). Salivation response was most notably associated with tumour location, tumour stage 
and treatment (Table 1). Two-thirds (69%, 31/45) of patients with too much saliva had 
tumours located in the oral cavity, compared to 51% (41/80) of those with saliva of normal 
consistency and 38%, (62/163) of those deficient in saliva to a lesser or greater degree. One-
quarter (26%, 21/80) of those with normal consistency had advanced stage 3-4 disease, in 
contrast to most other patients, range 60-75% among the four other groups (60% for those 
with too much saliva).  Three-quarters (76%, 61/80) of those with normal consistency were 
treated only by surgery, compared to 47% (21/45) with too much saliva and 21% (34/163) of 
those deficient in saliva to a lesser or greater degree. Those with too much saliva had higher 
observed rates of free-flap use during surgery, and higher levels of comorbidity, than patients 
in the other four groups.   
 
Salivation response was associated strongly with most other measures of HRQOL (Table 2). 
Patients with saliva of normal consistency and those with ‘less saliva than normal but 
enough’ consistently reported better HRQOL than other patients. In terms of the key outcome 
measures of the trial, 51% (23/45) of those with too much saliva reported overall QOL that 
was less than good, 60% (27/45) had distress thermometer values of 4 or above, and the 
median (IQR) UWQOL social-emotional composite score was 62 (37-73). These results were 
similar to or worse than those with too little saliva or with no saliva at all and this was a 
consistent observation across all the HRQOL measures. If for pragmatic reasons having too 
little or too much saliva were scored the same (i.e. as 30), then the median (IQR) full physical 
function composite score was 69 (54-86).  If having too much saliva was treated in the same 
way as having too little saliva in triggering an algorithm to identify a significant 
problem/dysfunction, i.e. that the issue was important to the patient, then 34% (99) were 
affected. This compares to 27% (77) if the trigger only applied to those with too little saliva.  
 
For the 140 patients in the trial group that completed an electronic PCI prompt sheet 
immediately prior to their outpatient consultation, the main items they selected for discussion 
are shown in Table 3, and these are stratified by how patients responded about salivation.  
Patients with too much saliva most commonly selected ‘chewing/eating’ (55%), 
‘fatigue/tiredness’ (45%), ‘salivation’ (41%), ‘fears of cancer coming back’ (36%), 
‘swallowing’ (36%), ‘pain in head and neck’ (32%), ‘shoulder’ (32%), ‘sore mouth’ (32%) 
and ‘speech/voice /being understood’ (32%). Most of those lacking saliva to a lesser or 
greater degree selected ‘dry mouth’ (76%, 59/77), and other common items they selected 
included ‘salivation’, ‘swallowing’, ‘chewing/eating’, ‘taste’, ‘dental health/teeth’, ‘sore 
mouth’, ‘energy’, ‘fatigue/tiredness’, ‘pain the in head and neck’, and ‘fears of the cancer 
coming back’.  Patients with normal consistency selected fewer items with ‘fears of the 





The study represents a large sample of HNC patients participating in a multicentre trial. The 
addition of more focused questioning on the concept of “I have too much saliva” has allowed 
for greater precision in collecting data regarding the impact of saliva on QOL. However, it is 
important to note that no objective data on saliva flow is available to support these 
perceptions. Longer, longitudinal data may give more data as to how patients see this 
impacting on their lives.  
 
Sixteen percent of the participants reported too much saliva as a problem. Tumour location 
had a significant association with this, 69% of such patients having tumours in the oral 
cavity. Further subsite analysis is not available, as it maybe that it is the control of saliva in 
the oral cavity that of an issue than actual increased flow of saliva. This is also reinforced by 
a clear association with free flap reconstruction, again which may alter the oral anatomy. 
Increased saliva flow is also associated with increased co morbidities, the implication of 
which is not as clear.  
 
Historically, the UWQOL has had an evenly spaced scoring system for its domains: 0 25 50 
75 100 for five response options, 0 30 70 100 for four options, or 0 50 100 for three, these 
being based on hierarchy in severity of response. This has merit in being simple and 
pragmatic. The new 'too much saliva' response option must find a place in the hierarchy of 
response based on severity and impact on the patient, and needs to be allocated a score. We 
tend now not to report domain scores per se and rely more on whether the UWQOL 
responses indicate significant problems or dysfunction in regard to each domain. However, 
the saliva domain score is important for computing the UWQOL physical function composite 
score, which is the mean of the six component domain scores that make up the subscale. 
 
 Our study results suggest that having 'less saliva than normal but enough' seems to impact 
less on patients than 'having too much', while across the various HRQOL measures recorded 
those with too much saliva had similar results to those with too little saliva or with no saliva 
at all.  If these are reasonable measures to make such judgements then this suggests a suitable 
score for the ‘too much saliva’ option at the lower end of the 0-100 scale, and it is difficult 
from these data to be more precise. For pragmatic reasons of making the scale as simple as 
possible moving forwards we recommend giving equal weight to having too little and having 
too much, i.e. a score of 30. However, the two should remain as separate options as viewed 
on the UWQOL questionnaire and should not to be merged into a single response option -
their wording should be – ‘I have too little saliva’ and ‘I have too much saliva’.  
 
A significant problem or dysfunction with salivation has previously been indicated either by 
someone having no saliva at all or by someone having too little saliva and stating that 
salivation had been one of at most three issues important to them in the past week.  In 
keeping with the above scoring we now recommend that having too much saliva and this 
being important should also be added as an indicator of dysfunction. In this patient 
population, this raised the rate of dysfunction by 7% from 27% to 34%. Further research in 
collecting more detailed concurrent salivation data on salivation issues alongside the 
UWQOL would help assess the validity of this recommendation. The EORTC HN43 has 




Strategies exist for the management of too much saliva in the HNC patient. It is important to 
identify this subset. It is an area that requires further research to develop a robust treatment 






Having too much saliva for post treatment HNC patients can have a detrimental impact on 
thei HRQOL with further research needed as to how best to manage this. Historically under 
reported and not always considered by clinicians it is clear that its scoring in the UW-QOL 
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Table 1.  UWQOL salivation  and case-mix   
 
  
I have no 
saliva 
I have too 
little saliva 
I have less 
saliva than 
normal, but it 
is enough 
My saliva is of 
normal 
consistency 
I have too 
much saliva 
P value* 
 All patients 15 91 57 80 45  
Gender Female 33% (5) 26% (24) 35% (20) 29% (23) 40% (18) 0.50 
Age (diagnosis)  Median (IQR) 63 (50-68) 61 (54-66) 59 (55-67) 64 (56-73) 63 (58-73) 0.06 KW 
Tumour site Oral cavity 27% (4) 35% (32) 46% (26) 51% (41) 69% (31) 
<0.001 
 Oropharynx 60% (9) 43% (39) 44% (25) 10% (8) 22% (10) 
 Larynx - 14% (13) 5% (3) 29% (23) 4% (2) 
 Other 13% (2) 8% (7) 5% (3) 10% (8) 4% (2) 
Overall stage Advanced 3-4 67% (10) 75% (68) 67% (38) 26% (21) 60% (27) <0.001 
Treatment Surgery only 13% (2) 19% (17) 26% (15) 76% (61) 47% (21) 
<0.001  RT or RT/CT only 40% (6) 32%  (29) 19% (11) 9% (7) 11% (5) 
 Surgery & RT or 
RT/CT 47% (7) 49% (45) 54% (31) 15% (12) 42% (19) 
Free-flap Yes 44% (4/9) 27% (17/62) 30% (14/46) 19% (14/73) 45% (18/40) 0.05 
Comorbidity WHO 1-4 27% (4) 41% (37) 30% (17) 35% (28) 51% (23) 0.19 
 ACE27 
Mod/Severe 7% (1) 19% (17) 18% (10) 16% (13) 33% (15) 0.13 
Consultation time Median (IQR) 10 (7-12) 11 (8-16), 
n=90 










Table 2.  UWQOL salivation  and case mix 
 
  
I have no 
saliva 
I have too 
little saliva 
I have less 
saliva than 
normal, but 
it is enough 
My saliva is 
of normal 
consistency 
I have too 
much saliva 
P value * 




Appearance 13% (2) 14% (13) 7% (4) 3% (2) 16% (7) 0.03 
Swallowing 27% (4) 20% (18) 7% (4) 4% (3) 29% (13) <0.001 
Chewing 40% (6) 15% (14) 4% (2) 3% (2) 31% (14) <0.001 
 Speech 13% (2) 11% (10) 2% (1) 1% (1) 20% (9) <0.001 
 Taste 53% (8) 26% (24) 16% (9) 6% (5) 24% (11) <0.001 




Pain 47% (7) 29% (26) 28% (16) 13% (10) 53% (24) <0.001 
Activity 20% (3) 11% (10) 12% (7) 8% (6) 18% (8) 0.34 
Recreation 13% (2) 10% (9) 2% (1) 5% (4) 16% (7) 0.05 
 Shoulder 7% (1) 10% (9) 14% (8) 6% (5) 29% (13) 0.009 
 Mood 27% (4) 25% (23) 4% (2) 4% (3) 29% (13) <0.001 
 Anxiety 27% (4) 29% (26) 7% (4) 4% (3) 27% (12) <0.001 
Composite score Median (IQR) 61 (46-70) 70 (54-83) 76 (66-91) 88 (78-96) 58 (48-75) <0.001KW 
Intimacy Dysfunction 33% (5) 9% (8) 0% (0) 0% (0) 4% (2) <0.001 
Fear of recurrence Dysfunction 27% (4) 33% (30) 30% (17) 11% (9) 33% (15) 0.005 
Overall QOL Less than good 33% (5) 40% (36) 26% (15) 13% (10) 51% (23) <0.001 
Distress 
thermometer 
≥4 67% (10) 53% (48) 37% (21) 29% (23) 60% (27) <0.001 
EQ-5D-5L        
Mobility Mod/Sev/Un 47% (7) 23% (21) 11% (6) 14% (11) 44% (20) <0.001 
Self-care Mod/Sev/Un 33% (5) 13% (12) 2% (1) 6% (5) 20% (9) 0.001 
Usual activities Mod/Sev/Un 53% (8) 25% (23) 18% (10) 13% (10) 44% (20) <0.001 
Pain Discomfort Mod/Sev/Ext 47% (7) 38% (35) 21% (12) 14% (11) 51% (23) <0.001 
Anxiety Depression Mod/Sev/Ext 40% (6) 25% (23) 5% (3) 4% (3) 29% (13) <0.001 











EQ- 5D VAS Median (IQR) 60 (45-75) 71 (50-82) 80 (70-87) 81 (71-90) 63 (50-82) <0.001KW 
 
*Fishers exact test apart from KW (Kruskal-Wallis test) 




TTO: EQ-5D-5L TTO crosswalk values 
VAS:  The EQ-5D self-reported questionnaire includes a visual analog scale (VAS), which records the respondent's self-rated 




















































I have no saliva I have too little saliva I have less saliva than normal, 
 but it is enough 
My saliva is of normal consistency I have too much saliva  
N=4 N=52 N=21 N=41 N=22 
Dry mouth (100%) Dry mouth (83%) Dry mouth (52%) Fear of cancer coming back (29%) Chewing/Eating (55%) 
Energy levels, Fatigue/tiredness, 
Salivation  (all 75%) 
Salivation (58%) Fear of cancer coming back (38%) Dental health/teeth (24%) Fatigue/tiredness (45%) 
Dental health/teeth (48%) Dental health/teeth,  




Fear of cancer coming back,  
Swallowing (both 36%) 
Chewing/Eating, Dental 
health/teeth, Swallowing, Taste (all 
50%) 
Energy levels (29%)  
Mucus, Taste (both 38%) 
Chewing/Eating, Pain in head and 
neck, Swallowing, Taste (all 24%) 
 
Pain in head and neck, Shoulder, 
Sore mouth, Speech/Voice/being 
understood (all 32%) 
 
Fear of cancer coming back, 
Fatigue/tiredness (both 37%) 
 
15 other items all 25%  
 Pain in head and neck, 
Shoulder, Sore mouth (all 29%) 
  
Dry mouth, Mucus, Taste,  
Weight (all 27%) 
   
   
 Appetite, 
Mouth opening (both 27%) 
  
   
Appetite, Coughing, 
Mouth opening (all 23%)  Cancer treatment, 
Weight (both 25%) 
  
   
 Hearing (23%)    
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